Group Mailing 2026-10-01

Priority Lists

Disease Committee	Last Changed
Breast Cancer	3/6/26
Cancer Care Delivery	8/15/26
comboMATCH	10/16/25
Early Therapeutics & Rare Cancers	11/7/25
Gastrointestinal Cancer	8/4/26
Genitourinary Cancer	4/9/26
Head and Neck Cancer	10/16/25
iMATCH	12/3/25
Immunomolecular Therapeutics	12/3/25
Leukemia	10/2/26
Lung Cancer	9/8/25
LungMAP	4/24/25
Lymphoma	10/23/25
Melanoma	11/7/25
Myeloma	10/23/25
myeloMATCH	7/29/26
Other	2/1/14
Palliative Care	10/24/25
Prevention, Screening, and Surveillance	1/1/25
Sarcoma	9/15/07
SWOG CTP	7/29/26
Symptom Management and Survivorship	10/24/25

Scroll Table

Activations

S2012Phase II-III

Reactivation of Arm 1 & Arm 3 - Effective Date 9/17/2026

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Action Codes	AC, ER, NR
Study Coordinator(s)	David B. Zhen, MD
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

S2507Phase II

Initial Activation - Effective Date 9/22/2026

A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)

Action Codes	FBR
Study Coordinator(s)	Ibrahim Aldoss, M.D., Anjali S. Advani, M.D.
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

SN2426Phase II

Re-Activation - Effective Date 9/28/2026

A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma

Action Codes	NR
Study Coordinator(s)	Paul Swiecicki, M.D,
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Closures

Amendments, Revisions, Memoranda

S1404

Memorandum - Updated Continuing Review Application and CIRB Study Status

A Phase III Randomized Trial of Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma

Action Codes	ER
Study Coordinator(s)	Kenneth F. Grossmann, M.D., Ph.D, Sapna Patel, MD
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

S1501

Revision #9 - Version Date 6/01/2026

Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Action Codes	ER
Study Coordinator(s)	Justin D. Floyd, D.O., Monika Leja, M.D., Carol Fabian, M.D., Andrew Godwin, Ph.D.
Participants	CTSU Institutions in the United States, ECOG-ACRIN, ALLIANCE, NRG

S1714QoL

Revision #9 - Version Date 8/14/2026

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Action Codes	ER
Study Coordinator(s)	Meghna Trivedi, M.D., Dawn Hershman, M.D., M.S., Daniel Hertz, PharmD, Ph.D., Stephanie Smith, RN, MSN, OCN
Participants	ALL NCORP COMPONENTS AND SUBCOMPONENTS, SWOG

S1929Phase II

Revision #12 - Version Date 7/16/2026

Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

Action Codes	AC, ER
Study Coordinator(s)	Nagla Karim, M.D., Ph.D, Karen Reckamp, M.D., Lauren A. Byers, M.D., Carl Gay, M.D., Ph.D

S2012Phase II-III

Revision #5 - Version Date 7/24/2026

Action Codes	AC, ER, NR
Study Coordinator(s)	David B. Zhen, MD
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

S2419Phase II-III

Memorandum 2 of 2 - S2419 MO-03 Investigator Brochure Access

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)

Action Codes	NR
Study Coordinator(s)	Pedro Barata, M.D., Ulka N. Vaishampayan, M.D., Sumanta K. Pal, M.D., David J. McConkey, Ph.D.
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS